Cambridge-based Abselion has secured £6.6 million in Series A financing to commercialise its Amperia protein analyser system, which enables rapid at-line quantification of antibodies, AAVs and other proteins from crude samples. The funding round was led by M Ventures, with participation from new and existing investors.

The Series A financing round, led by M Ventures, the strategic corporate venture capital arm of Merck, included new investors BioProcess 360 Partners and Untitled Ventures, alongside existing investors BGF, R42 and others. Oliver Hardick from M Ventures and Chris Major of BioProcess 360 Partners have joined Abselion’s Board of Directors.

Ruizhi Wang, CEO of Abselion

Novel electrochemical detection platform

The Amperia system utilises proprietary Redox Electrochemical Detection (RED) technology to deliver automated at-line measurement capabilities. The benchtop instrument enables direct quantification of biological molecules from crude samples in approximately one minute, providing immediate data access for process development and optimisation.

Applications in bioprocessing

The technology aims to address key analytical bottlenecks in bioprocess development and manufacturing, where rapid access to quantitative data can significantly impact process optimisation decisions. The system has been designed for accessibility across different laboratory and process environments.

Commenting on the investment, Ruizhi Wang, CEO of Abselion, said: “We are delighted to have the support of our investment partners to advance our mission to provide scientists with critical real-time data at the point of need. The Amperia RED technology delivers the accuracy, speed and agility required for insights that enable confident decision-making, driving bioprocess optimisation and innovation.”

Focus on process development

Dr Oliver Hardick of M Ventures highlighted the system’s potential impact on bioprocess development: “Providing meaningful data as close to the process as possible is a crucial pillar of enabling improved bioprocess development and manufacturing robustness. Abselion’s Amperia system does exactly this by delivering gold-standard insights in minutes that Bioprocess teams typically wait days for.”